Puma Biotech Offers Results Of Patient-Reported Outcomes In Phase II CONTROL Trial Of Neratinib In Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer At San Antonio Breast Cancer Symposium
Benzinga Newsdesk